Mathias Viard Selected Research

Neoplasms (Cancer)

1/2023	Divergent HLA variations and heterogeneous expression but recurrent HLA loss-of- heterozygosity and common HLA-B and TAP transcriptional silencing across advanced pediatric solid cancers.
12/2022	NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer.
1/2022	HLA-A*03 and response to immune checkpoint blockade in cancer: an epidemiological biomarker study.
6/2020	Characterization of Cationic Bolaamphiphile Vesicles for siRNA Delivery into Tumors and Brain.
10/2018	Design and biological activity of novel stealth polymeric lipid nanoparticles for enhanced delivery of hydrophobic photodynamic therapy drugs.
9/2015	Bolaamphiphiles as carriers for siRNA delivery: From chemical syntheses to practical applications.
3/2013	In Silico, In Vitro, and In Vivo Studies Indicate the Potential Use of Bolaamphiphiles for Therapeutic siRNAs Delivery.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Mathias Viard Research Topics

Disease

7	Neoplasms (Cancer) 01/2023 - 03/2013
6	Infections 01/2024 - 01/2004
6	Breast Neoplasms (Breast Cancer) 01/2020 - 01/2015
2	HIV Infections (HIV Infection) 01/2024 - 01/2019
2	Acquired Immunodeficiency Syndrome (AIDS) 01/2024 - 11/2020
2	Urinary Bladder Neoplasms (Bladder Cancer) 12/2022 - 01/2022
2	Melanoma (Melanoma, Malignant) 11/2018 - 01/2004
1	Osteosarcoma (Osteogenic Sarcoma) 01/2023
1	Ewing Sarcoma (Sarcoma, Ewing) 01/2023
1	Sarcoma (Soft Tissue Sarcoma) 01/2023
1	Glioma (Gliomas) 01/2023
1	Rhabdomyosarcoma 01/2023
1	Malaria 01/2022
1	Renal Cell Carcinoma (Grawitz Tumor) 01/2022
1	Parasitemia 01/2021
1	Communicable Diseases (Infectious Diseases) 01/2021
1	Aplastic Anemia (Anemia, Hypoplastic) 01/2020
1	Esophageal Neoplasms (Esophageal Cancer) 05/2019
1	Disease Progression 01/2019
1	Prostatic Neoplasms (Prostate Cancer) 10/2016
1	Human Influenza (Influenza) 03/2012
1	Virus Diseases (Viral Diseases) 05/2008

Drug/Important Bio-Agent (IBA)

4	RNA (Ribonucleic Acid)IBA 01/2023 - 03/2016
4	Small Interfering RNA (siRNA)IBA 06/2020 - 01/2015
3	HLA Antigens (Human Leukocyte Antigens)IBA 01/2024 - 12/2022
3	VaccinesIBA 01/2022 - 05/2008
3	Peptides (Polypeptides)IBA 01/2022 - 11/2012
3	LipidsIBA 10/2018 - 01/2015
2	EpitopesIBA 01/2024 - 01/2023
2	HLA-B Antigens (HLA-B)IBA 01/2024 - 01/2023
2	HLA-A Antigens (HLA-A)IBA 01/2024 - 01/2022
2	tapasinIBA 01/2022 - 11/2020
2	Glycoproteins (Glycoprotein)IBA 12/2005 - 01/2004
2	GlycosphingolipidsIBA 01/2004 - 01/2004
1	transporter associated with antigen processing (TAP)IBA 01/2023
1	Histocompatibility Antigens Class IIBA 01/2023
1	AntigensIBA 01/2023
1	Histocompatibility Antigens Class IIIBA 01/2023
1	HLA-DR Antigens (HLA-DR)IBA 01/2023
1	B7-H1 AntigenIBA 12/2022
1	Programmed Cell Death 1 ReceptorIBA 12/2022
1	NivolumabIBA 01/2022
1	Sunitinib (Sutent)FDA Link 01/2022
1	Everolimus FDA Link 01/2022
1	Biomarkers (Surrogate Marker)IBA 01/2022
1	avelumabIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2022
1	Messenger RNA (mRNA)IBA 01/2022
1	Axitinib (AG 013736)IBA 01/2022
1	DNA (Deoxyribonucleic Acid)IBA 11/2021
1	KIR ReceptorsIBA 01/2021
1	LigandsIBA 01/2021
1	HLA-C Antigens (HLA-C)IBA 01/2021
1	bolaamphiphileIBA 06/2020
1	PolymersIBA 01/2020
1	HLA-DPB1 antigen (HLA DPB1)IBA 01/2020
1	chlorinIBA 05/2019
1	2-(1-hexyloxyethyl)-2-devinyl pyropheophorbide-a (HPPH)IBA 05/2019
1	Photosensitizing Agents (Photosensitizers)IBA 05/2019
1	pyropheophorbide aIBA 05/2019
1	Long Noncoding RNAIBA 01/2019
1	CCR5 Receptors (CCR5 Receptor)IBA 01/2019
1	NucleotidesIBA 11/2018
1	1-phenyl-3,3-dimethyltriazene (PDT)IBA 10/2018
1	OximesIBA 01/2015
1	Ether (Diethyl Ether)IBA 01/2015
1	Hydroxyl RadicalIBA 01/2015
1	Antiviral Agents (Antivirals)IBA 11/2012
1	safingol (sphinganine)IBA 11/2012
1	Detergents (Detergent)IBA 03/2012
1	Neuraminidase (Sialidase)IBA 05/2008

Therapy/Procedure

3	Immunotherapy 01/2024 - 12/2022
2	Therapeutics 01/2022 - 03/2013
1	Precision Medicine 01/2023
1	Aftercare (After-Treatment) 01/2022
1	Drug Therapy (Chemotherapy) 10/2018